Polynovo Ltd
Company Profile
Business description
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Contact
320 Lorimer Street
Unit 2
Port MelbourneVIC3207
AUST: +61 386814050
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2025
Employees
8
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,480.10 | 29.20 | 0.35% |
CAC 40 | 7,216.83 | 10.15 | -0.14% |
DAX 40 | 19,003.11 | 30.53 | -0.16% |
Dow JONES (US) | 43,958.19 | 47.21 | 0.11% |
FTSE 100 | 8,030.33 | 4.56 | 0.06% |
HKSE | 19,626.26 | 197.19 | -0.99% |
NASDAQ | 19,230.72 | 50.68 | -0.26% |
Nikkei 225 | 38,936.36 | 214.70 | 0.55% |
NZX 50 Index | 12,679.21 | 4.72 | 0.04% |
S&P 500 | 5,985.38 | 1.39 | 0.02% |
S&P/ASX 200 | 8,227.40 | 34.00 | 0.41% |
SSE Composite Index | 3,439.27 | 0.00 | -0.00% |